PYXS (Pyxis Oncology) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pyxis Oncology's Free Cash Flow for the three months ended in Sep. 2024 was $-14.67 Mil. Pyxis Oncology's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Pyxis Oncology's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Pyxis Oncology's current FCF Yield % is -56.80%.

The historical rank and industry rank for Pyxis Oncology's FCF Margin % or its related term are showing as below:

PYXS' s FCF Margin % Range Over the Past 10 Years
Min: -333.66 Med: 0 Max: 0
Current: -333.66

PYXS's FCF Margin % is ranked worse than
61.44% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs PYXS: -333.66

Pyxis Oncology FCF Margin % Historical Data

The historical data trend for Pyxis Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology FCF Margin % Chart

Pyxis Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Pyxis Oncology Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial														-	-	-129.73	-	-

Competitive Comparison of Pyxis Oncology's FCF Margin %

For the Biotechnology subindustry, Pyxis Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pyxis Oncology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pyxis Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pyxis Oncology's FCF Margin % falls into.

Pyxis Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pyxis Oncology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-77.435	/	0
	=	%

Pyxis Oncology's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-14.665	/	0
	=	%

Pyxis Oncology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pyxis Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.pyxisoncology.com

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Executives

Pamela Ann Connealy	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane	officer: Chief Accounting Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan	director, officer: Chief Executive Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont	director	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin	other: Former Director	20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst	officer: Chief Scientific Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140